A peptide vial can show exceptionally high purity and still contain the wrong amount of the advertised compound. That is the central finding of an April 2026 preprint examining more than 6,000 independent laboratory reports on gray-market peptides.

The analysis reported median purity of 99.8%, yet 41.6% of reports failed a combined standard for purity and labeled amount. Some samples lacked the stated peptide altogether, while endotoxin testing appeared in fewer than 4% of reports.

These findings complicate a familiar marketing message: high purity does not, by itself, establish accurate contents or comprehensive product quality. However, the research also requires careful interpretation. It is a preprint that has not been peer-reviewed, and its results describe the analyzed reports, not necessarily the entire gray market.

Gray-Market Peptide Testing: What the Research Examined

In their April 2026 preprint, Mendias and Awan analyzed 6,285 independent laboratory reports covering 203 vendors and 14 peptides, using Finnrick data.

This was a laboratory-report analysis, not a clinical trial. It examined product characteristics rather than whether a peptide produced a health benefit. The results therefore cannot establish effectiveness, clinical safety, or an appropriate way to use any compound.

The distinction between reports and vials also matters. Although the headline describes testing of more than 6,000 vials, the documented unit of analysis is 6,285 laboratory reports. That should not automatically be interpreted as a random sample of 6,285 unique products representing every seller or production batch.

The Main Findings at a Glance

• Median purity: 99.8% across the analyzed reports.
• Combined quality-standard failure: 41.6% failed a benchmark requiring 90–110% of the labeled amount and at least 98% purity.
• Missing stated peptide: 2.4% lacked the peptide identified on the label.
• Compound-specific findings: The stated peptide was absent in 10% of TB-500 reports and 9.1% of CJC-1295 reports.
• Limited endotoxin coverage: Endotoxin testing appeared in fewer than 4% of reports.

The combined failure rate is particularly important. It does not mean that 41.6% contained no peptide, nor does it mean that every failure involved low purity. A report could fail because the measured amount fell outside the specified range, purity fell below the threshold, or both.

Why High Peptide Purity Does Not Guarantee an Accurate Dose

Purity and quantity answer different questions

Purity describes how much of the measured material corresponds to the target compound under the analytical method used. Quantity describes how much of that compound is present. These measurements are related, but they are not interchangeable.

A sample can contain predominantly the correct peptide while holding less or more of it than the label states. Consequently, an impressive purity percentage does not establish that the labeled amount is accurate.

This is why the preprint’s 99.8% median purity and 41.6% combined failure rate are not contradictory. The first summarizes purity; the second evaluates whether reports met both purity and amount requirements.

Label accuracy is not the same as clinical dosing

Here, dose accuracy refers to agreement between measured contents and the amount advertised on a vial. It does not establish an appropriate human dose.

Similarly, the study’s 90–110% amount range is an analytical benchmark, not permission to use a research compound. Passing that benchmark would not establish that a product is approved, suitable for administration, or clinically effective.

It is also more precise to describe these findings as label-amount discrepancies rather than off-label use. Off-label prescribing is a separate medical and regulatory concept.

What the Missing-Peptide Results Mean

The preprint reported that 2.4% of analyzed reports lacked the stated peptide. Within the relevant compound groups, the reported proportions were 10% for TB-500 and 9.1% for CJC-1295.

These findings concern identity, not simply quantity. A product containing an unexpected amount of the correct compound presents a different analytical problem from a product in which the advertised compound is absent.

However, absence of the stated peptide does not automatically reveal what was present instead. Without further evidence, it would be inappropriate to assume that every such sample was empty, contained a particular substitute, or reflected deliberate misconduct.

TB-500 and CJC-1295 are not FDA-approved drugs. Their appearance in laboratory reports does not establish an approved medical use, and analytical testing cannot substitute for clinical evidence.

The Endotoxin Testing Gap

One of the most consequential limitations was the small proportion of reports addressing endotoxins. According to the preprint, fewer than 4% included endotoxin testing.

Endotoxin testing addresses a different question from peptide identity, purity, or amount. A purity result alone cannot establish the absence of bacterial endotoxins. Likewise, endotoxin testing and sterility testing are distinct assessments.

The limited coverage leaves a substantial information gap. It does not prove that untested samples were contaminated, but it also does not justify assuming they were free of endotoxins.

This distinction is essential when evaluating certificates of analysis. A report can be accurate about the characteristics it measured while offering no evidence about characteristics outside its testing scope.

How to Read a Peptide Certificate of Analysis

The research supports reading laboratory documentation as a collection of separate findings, rather than treating a single purity number as an overall quality guarantee.

• Identity: Does the testing establish that the advertised peptide is present?
• Amount: Does the report measure total peptide content, rather than only relative purity?
• Purity: What does the reported percentage represent under the stated method?
• Sample linkage: Is the tested sample clearly connected to a particular lot or batch?
• Testing scope: Which contamination-related assessments were performed, and which were not?

Even a detailed report describes the submitted sample. It does not automatically establish consistency across other batches, storage conditions, or later shipments. Independent testing adds evidence, but the scope of that evidence still matters.

Compounding Status Is Not FDA Approval

Regulatory terminology can create another source of confusion. An August 2026 AJMC explainer emphasizes that Category 1 compounding status is not FDA approval.

A category associated with a compounding framework should not be read as an endorsement of a gray-market vial, proof of clinical benefit, or certification of a seller’s manufacturing practices.

These are separate questions: whether a substance has a particular regulatory status, whether a specific product meets analytical specifications, and whether a treatment has evidence supporting a particular medical use. Evidence addressing one question does not automatically answer the others.

What This Preprint Cannot Establish

The large dataset makes the analysis informative, but size alone does not eliminate uncertainty. Important questions include how samples entered the dataset, how testing methods compared, and how closely the reports reflect the broader market.

Because this was not a randomized market survey, 41.6% should not be presented as the failure rate for all gray-market peptide vials. Compound-specific percentages also need the context of their underlying sample sizes before making strong comparisons.

Peer review may further clarify the methods, interpretation, and limitations. Until then, the findings are best described as substantial preliminary evidence of inconsistent label accuracy within the analyzed reports.

The Bottom Line

The clearest lesson is that peptide purity, identity, labeled amount, and contamination testing are separate dimensions of quality. A strong result in one category cannot fill an evidence gap in another.

The April 2026 preprint found very high median purity alongside frequent failures of a combined purity-and-amount benchmark, occasional absence of the advertised peptide, and limited endotoxin testing. Those findings warrant scrutiny—not assumptions that every product is defective or that a passing report makes a research compound suitable for human use.